[ad_1]
(Fight against neo-coronary pneumonia) The “two guarantees” and the “one breakthrough” from production to vaccination of China’s new crown vaccine
China News Service, Beijing, March 15 (Reporter Gao Kai) As the new coronavirus vaccination spreads here, issues related to vaccination, production and supply have attracted wide attention. The Joint Prevention and Control Mechanism of the State Council of China held a press conference on the 15th. Give a concentrated and detailed explanation on this.
At the press conference that day, officials and experts from China’s National Health Commission said that from production to transportation to vaccination, Chinese officials have taken various measures to ensure the safety of the new corona vaccine. At the same time, they have also focused on the supply of materials and the approval process to ensure the supply of vaccines. In view of the potential impact of the novel coronavirus mutation in the future, “plan ahead and actively prepare” for vaccine research and development.
Guarantee the security
Li Bin, deputy director of China’s National Health Commission, said on the same day that as of March 14, a total of 64.98 million people were vaccinated against the new coronavirus in the country. Vaccination is advanced for key groups, high-risk groups, and other groups.
Li Bin said that in order to ensure the safety of vaccination, in terms of monitoring the flow of vaccines, the official establishment of a national electronic vaccine traceability collaboration platform, all regions timely and accurately report the required information to the platform, so that the vaccine can be traced throughout the process, the origin of the vaccine can be verified, and the destination can be traced. In terms of managing the safety of the circulation and use of vaccines, disease control agencies and vaccination units strictly control the entry and exit of vaccines, and regularly monitor and record the temperature of the new coronavirus vaccine. during storage and transportation to ensure the safety of storage and transportation. .
Li Bin said that the official organization also organized general hospitals above the second level to be responsible for medical treatment and support of vaccination points, sent experienced emergency first aid personnel to carry the necessary medical equipment, medicines and other warranties parked, and sent 120 ambulances to the scene. Strict training must be provided to personnel involved in medical treatment to ensure that suspected abnormal reactions can be identified and treated promptly.
Regarding how to ensure the quality and safety of the production of the new corona vaccine, Yuan Lin, Director of the Drug Supervision Department of the China National Medical Products Administration, said that China’s vaccine supervision level has been recognized internationally. In terms of laws and regulations, China is the only country that has specifically issued the “Vaccine Management Law”, which makes the relevant vaccination companies and institutions have laws and regulations to follow.
He noted that in terms of ensuring the quality of vaccines, special emphasis was placed on highlighting that vaccine manufacturers are primarily responsible for the quality of vaccines and must implement the relevant responsibilities in accordance with the law. First, strictly implement vaccine production management specifications; second, organize production in strict accordance with the state-approved vaccine production process; third, strictly require companies to conduct vaccine factory inspection and delivery requirements; fourth, rapidly collect specialty vaccines after the vaccination response to ensure the safety of the entire vaccine chain.
Yuan Lin revealed that the State Food and Drug Administration has sent two professional inspectors to vaccine manufacturers to monitor them continuously, and will also carry out spot checks and inspections of manufacturers with the relevant local authorities.
Secure supply
Regarding the production capacity and production of China’s new crown vaccine, Tian Yulong, a member of the party group and chief engineer of the Ministry of Industry and Information Technology of China, said on the same day: “The Current supply demand has been better met. And everyone has seen that our foreign assistance and exports have received a good response., Supporting international demand. “
He noted that domestic vaccine manufacturers are still expanding. With the continuous release of production capacity, production will gradually increase. “In accordance with the current production plan, we have established a dynamic balance guarantee mechanism for production supply and demand.”
Regarding the supply of raw materials for vaccine production, Tian Yulong said that at present, China’s production system is complete and complete. Now the supply of raw materials for vaccine production is orderly, stable and sufficient, which can meet the present and future. large-scale vaccine production needs.
Wang Junzhi, deputy director of the vaccine research team of the research team and academic of the Chinese Academy of Engineering, presented on the same day that in addition to the four vaccines currently approved for commercialization, there are currently 17 new corona vaccines in China that have entered the clinical stage, and 4 have been conditionally approved. The other three technical routes are basically in the clinical phase of phase III or will soon enter the clinical phase of phase III.
As to whether the batch issuance procedures that must be approved before the vaccine can be released can meet the large-scale production of new coronavirus vaccines, Yuan Lin said on the same day as today, including agencies national drug inspection agencies, provincial drug inspection agencies. such as Beijing, Hubei and Guangdong have the ability to inspect and batch issue new coronavirus vaccines. More than a dozen inspection agencies at the provincial level are expected to have the capacity to inspect and issue batch vaccines in the near future. By continuously strengthening the construction of batch issuance inspection capabilities, it is possible to ensure that the batch issuance and vaccine inspection capabilities are effectively coordinated and matched with the company’s growing production capacity.
Attach great importance to mutant strains “plan ahead and actively prepare”
Regarding the question of whether the variant strain of the new corona virus that is of concern to the public has an impact on the protection rate of China’s new corona virus, Wang Junzhi said on the same day that no one has been found. obvious impact.
He also noted, “We must attach great importance to this issue. Long-term spread of the virus can result in the accumulation of multiple mutations. When the accumulation reaches a certain level, there is a risk of affecting the protection of the vaccine. This risk it exists. To deal effectively with the mutation of the virus. We must plan ahead and actively prepare for the impact. “
In addition to closely monitoring and strengthening the vaccine platform construction, Wang Junzhi emphasized: “Actively research a new generation of vaccines. Once we worry about the situation, the virus mutation makes the vaccine immunity disappear or greatly reduce the situation, which can be developed in the shortest possible time. Vaccines against the strains are very critical. “Wang Junzhi said that, in general, the ability to deal with various virus variants should be improved by enhancement of comprehensive capabilities. (Finish)
